Imnadze Guram, Franz Norbert, Hofmann Steffen, Kowalski Marek, Billion Michael, Ferdosi Abbas, Warnecke Henning
Schuechtermann Klinik, Bad Rothenfelde, Germany.
Thorac Cardiovasc Surg. 2015 Sep;63(6):487-92. doi: 10.1055/s-0035-1549355. Epub 2015 May 25.
Transcatheter aortic valve implantation (TAVI) is a recognized therapeutic option for high-risk and inoperable patients with aortic valve stenosis. The choice of access route is a matter of debate. We are presenting our 5-year experience of transapical TAVI dominance.
This single-center study includes 575 patients. Two groups were compared: transapical (TA) and transfemoral (TF) with 454 and 121 patients, respectively. Individual access route decision was made by our heart team following a clinical and computed tomography (CT) data based nonbiased strategy. The same team performed all procedures. The mean logistic EuroSCORE was significantly higher in the TA group, however, without difference in STS score. The number of patients with coronary artery disease, previous cardiac surgery, and low left ventricular ejection fraction was higher in the TA group. There were no significant differences in age and presence of other comorbidities.
Procedural success in both TA and TF groups was high (97.9% and 97.6%). No patient died during the procedure. Patient survival (30 days: TF, 97.5% vs. TA, 95.7%; 1 year: TF, 94.6% vs. TA, 81.8%; 2 years: TF, 84.7% vs. TA, 76.7%; 3 years: TF, 59.9% vs. TA, 67.8%) and a low TF vascular complication rate (1.6%) are encouraging compared with other registry data.
A "no competition" team approach strategy along with an experienced hybrid team leads to fewer vascular complications and better outcomes for both TA and TF TAVI patients.
经导管主动脉瓣植入术(TAVI)是高危和无法进行手术的主动脉瓣狭窄患者公认的治疗选择。入路途径的选择存在争议。我们在此介绍经心尖TAVI主导的5年经验。
这项单中心研究纳入了575例患者。比较了两组:经心尖组(TA)和经股动脉组(TF),分别有454例和121例患者。我们的心脏团队根据基于临床和计算机断层扫描(CT)数据的无偏倚策略做出个体入路途径决策。同一团队进行所有手术。TA组的平均逻辑欧洲心脏手术风险评估系统(EuroSCORE)显著更高,然而,胸外科医师协会(STS)评分无差异。TA组中冠心病、既往心脏手术史和左心室射血分数低的患者数量更多。年龄和其他合并症的存在方面无显著差异。
TA组和TF组的手术成功率都很高(分别为97.9%和97.6%)。术中无患者死亡。与其他登记数据相比,患者生存率(30天:TF组为97.5%,TA组为95.7%;1年:TF组为94.6%,TA组为81.8%;2年:TF组为84.7%,TA组为76.7%;3年:TF组为59.9%,TA组为67.8%)以及TF组较低的血管并发症发生率(1.6%)令人鼓舞。
“无竞争”团队方法策略以及经验丰富的混合团队可使TA和TF TAVI患者的血管并发症更少且预后更好。